Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Lanifibranor in Healthy Chinese Adults
NCT06126562Phase 1Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Oct 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lanifibranor in Nonalcoholic steatohepatitis (NASH) (2 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Maximum concentration at 168 hours, Area under the plasma concentration-time curve at 168 hours and 8 more. Started Oct 2023; status: completed.
02
Drugs
lanifibranor
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT06126562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06126562.